Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast

被引:34
作者
Baqai, T
Shousha, S
机构
[1] Charing Cross Hosp, Dept Histopathol, London W6 8RF, England
[2] Imperial Coll Fac Med, Dept Histopathol, London, England
关键词
breast; breast carcinoma; ductal carcinoma in situ; lobular carcinoma in situ; oestrogen receptors; progesterone receptors; androgen receptors; c-erbB-2; p53;
D O I
10.1046/j.1365-2559.2003.01612.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To compare the morphological and immunohistochemical characteristics of oestrogen receptor (ER)-negative and ER-positive ductal carcinoma in situ (DCIS) of the breast, in an attempt to establish more objective criteria for the classification of DCIS. Methods and results: Sections of 64 cases of in-situ carcinoma of the breast were stained for ER, progesterone receptors (PgR), androgen receptors (AR), c-erbB-2 and p53, using the immunoperoxidase technique. The cases included 60 DCIS and four lobular carcinoma in situ (LCIS). Four DCIS lesions were associated with foci of microinvasion. The 60 DCIS cases included 31 high grade, 23 intermediate grade and six low grade. Twenty-four DCIS cases (40%) were ER-negative and 36 were positive. ER negativity was significantly associated with high nuclear grade (88% versus 27% for ER-positive cases, P < 0.001), PgR negativity (100% versus 25%, P < 0.001), c-erbB-2 positivity (79% versus 14%, P < 0.001) and p53 positivity (58% versus 6%, P < 0.001). There was no difference between ER-negative and -positive DCIS as regards AR expression, with 91% of cases in each group being AR-positive. Of the four cases of DCIS with microinvasion, three were ER- and PgR-negative, all four were c-erbB-2-positive and AR-positive and one was p53-positive. None of the four LCIS was ER, PgR or AR-negative and none was c-erbB-2- or p53-positive. Conclusions: There is a highly significant direct relationship between ER negativity in DCIS and high nuclear grade, PgR negativity and c-erbB-2 and p53 positivity. We suggest that immunohistological assessment of ER status may help in providing a more objective way of classifying DCIS.
引用
收藏
页码:440 / 447
页数:8
相关论文
共 41 条
[1]  
[Anonymous], PATH REP BREAST CANC
[2]  
BORBOW L, 1995, J PATHOL, V176, P333
[3]  
Bose S, 1996, ARCH PATHOL LAB MED, V120, P81
[4]  
BUR ME, 1992, CANCER-AM CANCER SOC, V69, P1174
[5]  
CHAUDURI B, 1993, SURGERY, V113, P134
[6]   Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast [J].
Douglas-Jones, AG ;
Morgan, JM ;
Appleton, MAC ;
Attanoos, RL ;
Caslin, A ;
Champ, CS ;
Cotter, M ;
Dallimore, NS ;
Dawson, A ;
Fortt, RW ;
Griffiths, AP ;
Hughes, M ;
Kitching, PA ;
O'Brien, C ;
Rashid, AM ;
Stock, D ;
Verghese, A ;
Williams, DW ;
Williams, NW ;
Williams, S .
JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (08) :596-602
[7]   Incidence of and treatment for ductal carcinoma in situ of the breast [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Grady, D ;
Henderson, IC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12) :913-918
[8]   Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Mamounas, E ;
Smith, R ;
Begovic, M ;
Dimitrov, NV ;
Margolese, RG ;
Kardinal, CG ;
Kavanah, MT ;
Fehrenbacher, L ;
Oishi, RH .
LANCET, 1999, 353 (9169) :1993-2000
[9]  
Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO
[10]  
2-Y